Literature DB >> 11444929

Expression and activity of ectopeptidases in fibrillating human atria.

U Lendeckel1, M Arndt, S Wrenger, K Nepple, C Huth, S Ansorge, H U Klein, A Goette.   

Abstract

Recent studies have demonstrated that atrial fibrillation (AF) occurs in the presence of degenerative changes of atrial tissue. In contrast, bradykinin (BK) appears to have cardioprotective effects diminishing myocardial hypertrophy and fibrosis. It is unknown, however, whether AF has direct effects on BK metabolism. Therefore, the purpose of this study was to determine the atrial expression of the membrane-bound peptidases, also referred to as ectopeptidases, carboxypeptidase M (CPM), dipeptidyl peptidase IV (DPIV), and alanyl-aminopeptidase (APN) in patients with and without AF. Atrial tissue samples of 35 patients undergoing open heart surgery were examined. Seventeen patients had chronic persistent AF (> or = 6 months; CAF), the remaining 18 patients (controls) had no history of AF. Peptidase expression was analyzed at the mRNA (quantitative RT-PCR) level and apparent changes were confirmed at the protein level. In case of unaltered mRNA levels, enzyme activity was determined. Reduced amounts of CPM-mRNA were found in patients with CAF (41.3+/-9.7 U nu controls: 86.1+/-17.5 U P<0.05). CPM protein was decreased to 47.5% in patients with CAF compared with controls (P<0.01). DPIV and APN mRNA amounts were similar in both groups. DPIV activity, however, was increased during CAF (219.6+/-30 pkat/mg protein v controls: 195.8+/-21.8 pkat/mg P<0.05). APN activity was unchanged. In conclusion, atrial bradykinin metabolizing activities are significantly altered during AF in humans. The observed alterations in ectopeptidase expression/activity may play a role in the structural remodeling of fibrillating atria. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11444929     DOI: 10.1006/jmcc.2001.1389

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  10 in total

Review 1.  Proteomics and transcriptomics in atrial fibrillation.

Authors:  Marc Sühling; Carmen Wolke; Christian Scharf; Uwe Lendeckel
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-01-09

2.  Serum protease activity in chronic kidney disease patients: The GANI_MED renal cohort.

Authors:  Carmen Wolke; Alexander Teumer; Karlhans Endlich; Nicole Endlich; Rainer Rettig; Sylvia Stracke; Beate Fiene; Simone Aymanns; Stephan B Felix; Anke Hannemann; Uwe Lendeckel
Journal:  Exp Biol Med (Maywood)       Date:  2016-12-30

3.  [Molecular biology of the heart atrium. New insights into the pathophysiology of atrial fibrillation as well as its clinical implications].

Authors:  A Goette; U Lendeckel; H U Klein
Journal:  Z Kardiol       Date:  2004-11

4.  Linagliptin prevents atrial electrical and structural remodeling in a canine model of atrial fibrillation.

Authors:  Tazuru Igarashi; Shinichi Niwano; Hiroe Niwano; Tomoharu Yoshizawa; Hironori Nakamura; Hidehira Fukaya; Tamami Fujiishi; Naruya Ishizue; Akira Satoh; Jun Kishihara; Masami Murakami; Junya Ako
Journal:  Heart Vessels       Date:  2018-05-02       Impact factor: 2.037

5.  Role of proteases in the pathophysiology of cardiac disease.

Authors:  Raja B Singh; Sucheta P Dandekar; Vijayan Elimban; Suresh K Gupta; Naranjan S Dhalla
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

6.  Effect of an ACE inhibitor and an AT1 receptor antagonist on cardiac hypertrophy.

Authors:  Chihiro Shikata; Atsushi Takeda; Nobuakira Takeda
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

Review 7.  Atrial Calpains: Mediators of Atrialmyopathies in Atrial Fibrillation.

Authors:  Alicja Bukowska; Uwe Lendeckel; Andreas Goette
Journal:  J Atr Fibrillation       Date:  2014-04-30

Review 8.  WNT signaling in atrial fibrillation.

Authors:  Carmen Wolke; Elmer Antileo; Uwe Lendeckel
Journal:  Exp Biol Med (Maywood)       Date:  2021-02-27

9.  A role for CETP TaqIB polymorphism in determining susceptibility to atrial fibrillation: a nested case control study.

Authors:  Folkert W Asselbergs; Jason H Moore; Maarten P van den Berg; Eric B Rimm; Rudolf A de Boer; Robin P Dullaart; Gerjan Navis; Wiek H van Gilst
Journal:  BMC Med Genet       Date:  2006-04-19       Impact factor: 2.103

10.  Clinical factors related to successful or unsuccessful cardioversion in the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) randomized trial.

Authors:  Gregory Y H Lip; Jose L Merino; Maciej Banach; Naab Al-Saady; James Jin; Michael Melino; Shannon M Winters; Monika Kozieł; Andreas Goette
Journal:  J Arrhythm       Date:  2020-04-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.